2020 POST-ASCO Professor Huang Cheng: Take a look at the hot spots of lung cancer research, understand the future direction of development, and explore more breakthrough opportunities.

!---- The 2020 POST-ASCO Conference Information Exchange on Lung Cancer was held in Yan, and the conference aims to deliver to domestic oncologists the latest research on lung cancer at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.the General Assembly to take the "online plus offline" approach to the simultaneous, one of the Presidents of the General Assembly, Fujian Province Cancer Hospital Professor Huang Cheng brought the "late NSCLC future direction" report.specialinvitation to Professor Huang Cheng to share forward advances in lung cancer research and to introduce the future direction of development.Huang Cheng, Second Class Physician, Professor, Chief Specialist of Fujian Cancer Hospital, Director of Oncology Internal Medicine and Research Office of Fujian Medical University, Director of the Center for Quality Control of Oncology Chemotherapy in Fujian Province, Standing Member of the Third, Fourth and Fifth Lung Cancer Committee of China Anticancer Association, Deputy Chairman of the Cancer Rehabilitation and Palliative Care Professional Committee of The Chinese Association of Cancer Cancer, Executive Committee of the Cancer Society of China, Executive Committee of the Chinese Society of Cancer Clinical Chemotherapy Deputy Chairman of the CSCO Small Cell Lung Cancer Expert Committee, Standing Committee of CSCO China Cancer Driven Gene Analysis Alliance, CSCO Vascular Targeting Expert Committee and BiomarkerS Expert Committee, CSWOG Lung Cancer Professional Committee Member, Wu Tianping Foundation Multidisciplinary Professional Committee, Member of the Cancer Professional Committee of the Chinese Pharmaceutical Society, Executive Director of Fujian Cancer Association, Chairman of the Fujian Cancer Association, Committee member of the Committee of The Anti-Cancer Association of Fujian Province, Chairman of the Committee of The Professional Committee of Oncology Medicine of Fujian Cancer Association.from the early/local late/late stage, to see the research progress of lung cancer in the field of attention this year's ASCO conference held online, lung cancer research progress has attracted much attention, this POST-ASCO conference information exchange session on lung cancer generally introduced the following aspects of research progress. The first aspect ofis early lung cancer, and in recent years, the auxiliary or new adjuvant targeted therapy, especially the third generation of EGFR-TKI-assisted therapy, has made great progress.in addition, the new auxiliary immunotherapy has also made great progress, some local advanced NSCLC patients through immunotherapy to achieve de-generation and re-surgery, found that a considerable number of patients after treatment of the tumor can achieve complete pathological relief.therefore, for patients with early lung cancer, the new immuno-assisted therapy deserves attention.second aspect, for local advanced lung cancer, we may pay more attention to the combination of radiation therapy-based treatment model and immunotherapy.PACIFIC clinical studies have concluded that local advanced lung cancer can be improved by about twice as much through standard synchrotron chemotherapy and immunosustained therapy. How cancombine radiation therapy with immunotherapy to achieve optimal results? This is the focus of ASCO this year. The third aspect ofis advanced lung cancer.whether targeted or immunotherapy, more research progress in advanced lung cancer is on the front line.targeted treatment, EGFR-TKI is now showing a "three generations of the same" pattern, the third generation of drugs can replace the first generation? Secondly, although the combination of TKI treatment has obtained better efficacy, but what kind of patients are suitable for combination therapy? TKI combined chemotherapy or combination immunotherapy or antivascular therapy? For ALK inhibitors, the efficacy of one/two/three generations of ALK inhibitors is very good, how to solve the problem of drug resistance is a very important development direction in the field of ALK in the future.for rare mutations, but also on the use of second-generation sequencing (NGS) to detect rare driving genes.at this year's ASCO conference, the rare mutation field has made great progress in met pathway abnormality and RET fusion mutation. The research on immunotherapy foradvanced lung cancer is very hot at present, and the combination of double immunotherapy is the focus of future attention.the future development direction of advanced NSCLC targeted therapy and immunotherapy will be briefly introduced from the perspective of oncologists and from the perspective of advanced non-small cell lung cancer (NSCLC) targeted treatment and immunotherapy.targeted therapy, it is divided into EGFR mutation, ALK positive and rare mutation.for EGFR-TKI, the current overall efficacy, the second generation is better than the first generation, three generations are better than the first generation.from the subgroup analysis of Total Survival (OS), it can be seen that some second-generation drugs may not be as effective as the 21L858R mutation population than the third generation of drugs.this has prompted us to wonder whether three-generation drugs can replace one- or two-generation drugs in the context of EGFR-TKI's "three generations of the same" system. And from subgroup analysis, 19del and 21L858R mutations on EGFR-TKI effect also seems to be different, so how to better use EGFR-TKI clinically, is an important direction for future research., the current EGFR-TKI combination therapy is used more, both combined chemotherapy, but also joint anti-angiogenesis therapy.whether to use EGFR-TKI combination therapy, first of all, should pay attention to the EGFR mutation-positive late-stage NSCLC patients whether there is a combined mutation.merged mutations are divided into two conditions, one for the EGFR pathway itself, such as 19del merge 21L858R, or the combined 18 or 20 exon mutation, which causes differences in efficacy in patients.also a combination of mutations is a combination of cancer-suppressing gene mutations, such patients with simple targeted treatment generally poor effect., future studies should conduct large Panel tests on EGFR mutations to distinguish between pure or complex mutations, and patients with compound mutations may be the main beneficiaries of combined therapy, and future targeted treatments for EGFR mutations will be more accurate.alK positive is somewhat different from EGFR mutation-positive late NSCLC.ALK positive is a golden mutation, the efficacy of these patients is better, the overall 5-year OS rate has been continuously improved.alK inhibitors currently have one, two, three generations of drugs, the key to explore which is the primary drug resistance mechanism, which is followed by the development of drug resistance mechanism.only by solving the problem of drug resistance can the ALK-positive NSCLC reach a new level of precision treatment.rare mutations are really difficult to find clinically, with some rates of only 1% or less.because the number of rare mutation patients is very small, so the relevant research must use the large Panel test screening patients, and use multi-center, basket test method spent in order to achieve better results. immunotherapy, the transition from immuno-monodrug therapy to combination therapy is due to the better efficacy of immuno-single-drug therapy for patients with high expression of PD-L1, while the proportion of such patients in clinical lying is low, and single-drug treatment can no longer meet clinical needs. immune combination therapy, there are currently immune combination chemotherapy, immunocombination anti-angiogenesis, the former has a relatively large number of research. clinical application, immunotherapy is still a certain distance from precision therapy, the future research direction has two points worthy of attention. first point, Biomarke's exploration is very important to achieve precision therapy. at present, Biomarkers such as PD-L1 expression and tumor mutation load (TMB) have some predictive effect on the clinical efficacy of immunotherapy, but they are not very accurate. in addition, we also need to study Biomarker, which is negatively related to the efficacy of immunotherapy, to understand why the efficacy is not good. so with regard to Biomarker, the future needs to be studied from a multidimensional perspective. the second point, how to improve the efficacy of immunotherapy. how to change the microenvironment of the tumor to change the "cold tumor" into "hot tumor", so that the role of immunotherapy more. from the hot spot of this year's ASCO conference, double immunotherapy is one of the important ways to improve the efficacy of immunotherapy in the future, and the relevant I-III clinical research is being carried out. can further observe the efficacy and safety of double immunotherapy through phase III clinical studies of double immunotherapy and immunotherapy single drugs. people believe that the two important development directions in the field of immunotherapy are the above-mentioned precision treatment and improve efficacy. focus on lung cancer research in China, and see if the future can lead China to lead the lung cancer country, many patients, resources are also many. in recent years, Chinese scholars in the targeted treatment and immunotherapy led the lung cancer research, basically in sync with the international, and even individual lyn at the leading level. china chest cancer research collaboration group (CTONG) and other associations have done a lot of work, the international influence is growing, the Chinese Society of Clinical Oncology (CSCO) lung cancer experts are also carrying out some important research. research carried out in China, such as the target new auxiliary treatment research of surgical system, the domestic third generation EGFR-TKI research of the internal medicine system, the precise research of immunotherapy, and even the research on the rare pathological type of lung adenocarcinoma, are being carried out, and the future is very worthy of expectation. MJ Source: Tumor Information, !-- Content Presentation Ends - !-- Determine Signed-Up